On 26 February 2019, orphan designation (EU/3/19/2142) was granted by the European Commission to 3R Pharma Consulting GmbH, Germany, for losartan for the treatment of epidermolysis bullosa.
|Disease / condition||
Treatment of epidermolysis bullosa
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: